Your browser is no longer supported. Please, upgrade your browser.
Settings
CRSP CRISPR Therapeutics AG daily Stock Chart
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-0.32 Insider Own3.60% Shs Outstand39.71M Perf Week1.54%
Market Cap761.24M Forward P/E- EPS next Y-3.01 Insider Trans-44.25% Shs Float22.39M Perf Month8.55%
Income-51.40M PEG- EPS next Q-0.70 Inst Own42.90% Short Float4.88% Perf Quarter0.52%
Sales11.00M P/S69.20 EPS this Y-194.70% Inst Trans1.88% Short Ratio4.16 Perf Half Y29.61%
Book/sh4.46 P/B4.30 EPS next Y-23.90% ROA-16.40% Target Price24.00 Perf Year-0.05%
Cash/sh6.38 P/C3.00 EPS next 5Y- ROE-24.90% 52W Range11.63 - 25.00 Perf YTD-5.38%
Dividend- P/FCF- EPS past 5Y- ROI-24.50% 52W High-23.32% Beta-
Dividend %- Quick Ratio21.30 Sales past 5Y- Gross Margin- 52W Low64.83% ATR0.97
Employees93 Current Ratio21.30 Sales Q/Q60.00% Oper. Margin- RSI (14)55.59 Volatility6.39% 5.07%
OptionableYes Debt/Eq0.00 EPS Q/Q-66.90% Profit Margin- Rel Volume3.80 Prev Close19.05
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume262.78K Price19.17
Recom2.30 SMA201.57% SMA502.47% SMA2006.31% Volume999,320 Change0.63%
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Dec-12-17 08:30AM  Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and -Thalassemia Business Wire
Dec-10-17 09:25PM  Cambridge biotechs among big winners at ASH blood disease conference American City Business Journals
07:45AM  CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for -Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting GlobeNewswire
Dec-07-17 07:00AM  CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in -thalassemia GlobeNewswire
Dec-05-17 08:00AM  CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for -Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting GlobeNewswire
07:47AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : December 5, 2017 Capital Cube
Nov-29-17 08:26PM  Bitcoin or CRISPR: Which is the Bigger Disruptor? Zacks
Nov-28-17 08:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-22-17 01:15PM  FDA warns against do it yourself gene therapy kits American City Business Journals
Nov-21-17 07:33AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : November 21, 2017 Capital Cube
Nov-14-17 07:34AM  Disruptor Alert: These 5 Companies Are Changing Healthcare Motley Fool
Nov-13-17 11:20AM  MIT scientists deploy new CRISPR delivery system to edit genes in mice American City Business Journals
08:00AM  CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer GlobeNewswire
05:00AM  CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs GlobeNewswire
Nov-10-17 08:00PM  CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting GlobeNewswire
Nov-08-17 04:05PM  CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Nov-07-17 03:48PM  Editas CEO to testify at U.S. Senate hearing on gene editing potential, ethics American City Business Journals
11:40AM  Why CRISPR Therapeutics AG Stock Edged Higher in October Motley Fool
08:00AM  CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting GlobeNewswire
07:04AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : November 7, 2017 Capital Cube
Oct-30-17 12:38PM  CRISPR Therapeutics AG Value Analysis (NASDAQ:CRSP) : October 30, 2017 Capital Cube
Oct-27-17 08:29AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : October 27, 2017 Capital Cube
Oct-13-17 08:30AM  CRISPR Therapeutics Awarded Grant from Friedreichs Ataxia Research Alliance to Collaborate with University of Alabama at Birmingham on Gene-edited Treatments for Friedrichs Ataxia GlobeNewswire
Oct-12-17 08:24AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : October 12, 2017 Capital Cube
Oct-10-17 10:00AM  Why CRISPR Therapeutics AG Stock Lost Ground in September Motley Fool
Oct-04-17 04:01PM  CRISPR Therapeutics to Present at Investor Conferences in October GlobeNewswire
Oct-02-17 07:30AM  CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer GlobeNewswire
Sep-27-17 08:17AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : September 27, 2017 Capital Cube
Sep-18-17 12:38PM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube
Sep-07-17 03:32PM  Breaking Down Barclays' New Bullish Calls On Biotech Benzinga
Aug-31-17 11:29AM  How a CRISPR, gene-editing technology, patent ruling could move stocks Harvest Exchange
Aug-24-17 10:50AM  CRISPR Therapeutics, MGH team up on new cancer treatments American City Business Journals +5.11%
Aug-22-17 07:30AM  CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies GlobeNewswire
Aug-13-17 11:01AM  This Technology Could Make You Rich -- and Change the World As We Know It Motley Fool
Aug-10-17 04:35PM  CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Aug-01-17 07:00AM  CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development GlobeNewswire
Jul-25-17 05:00PM  CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing GlobeNewswire
Jul-17-17 07:06AM  This Is Why Investors Will Need to Learn a New Acronym: CRISPR Motley Fool
Jul-15-17 03:40PM  Never Will I Ever Buy Preclinical Biotech Stocks. No Way! Motley Fool
12:03PM  Why You're Smart to Buy Vertex Pharmaceuticals Stock Motley Fool
Jul-10-17 12:35PM  Why CRISPR Therapeutics AG Jumped 11.7% in June Motley Fool
08:30AM  CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration GlobeNewswire
08:00AM  CRISPR Gene Editing Controversy: Does It Really Cause Unexpected Mutations? Forbes
Jul-09-17 06:02AM  3 Growth Stocks for Forward-Looking Investors Motley Fool
Jul-05-17 04:30PM  CRISPR Therapeutics to Present at the Piper Jaffray GenomeRx Symposium GlobeNewswire
Jun-23-17 08:14AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : June 23, 2017 Capital Cube
Jun-19-17 07:30AM  CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China GlobeNewswire
Jun-14-17 08:30AM  CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-07-17 08:30AM  CRISPR Therapeutics Appoints James R. Kasinger as General Counsel GlobeNewswire
Jun-06-17 03:20PM  Two gene editing firms unveil cancer drug pacts as ASCO comes to a close American City Business Journals
08:30AM  CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies GlobeNewswire
Jun-02-17 09:58AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-30-17 04:17PM  Here's Why Editas Medicine Fell as Much as 15.7% Today Motley Fool -5.32%
May-18-17 08:30AM  CRISPR Therapeutics Announces the Presentation of Data on its Lead Program at the Upcoming 22nd European Hematology Association Annual Congress GlobeNewswire
May-16-17 08:00AM  CRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to develop CRISPR/Cas9-based approaches for ALS GlobeNewswire
May-12-17 04:50PM  CRISPR Therapeutics to Present at Investor Conferences in May GlobeNewswire
May-11-17 08:30AM  CRISPR Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Provides Business Update GlobeNewswire
May-08-17 02:45PM  Cambridge gene editing firm CRISPR to use delivery tech honed at MIT American City Business Journals
08:00AM  CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT GlobeNewswire
May-04-17 08:00AM  CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations GlobeNewswire
Apr-27-17 08:00AM  CRISPR Therapeutics to Present at the 42nd Annual Deutsche Bank Health Care Conference GlobeNewswire
Apr-26-17 07:30AM  Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes GlobeNewswire
Apr-17-17 08:00AM  CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio GlobeNewswire
Apr-13-17 07:30AM  CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision GlobeNewswire
Apr-11-17 08:41AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : April 11, 2017 Capital Cube
Mar-31-17 04:33PM  CRISPR THERAPEUTICS AG Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.07%
Mar-30-17 08:00AM  CRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-28-17 08:00AM  CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing GlobeNewswire +11.95%
06:08AM  Coverage initiated on CRISPR Therapeutics by Chardan Capital Markets
Mar-23-17 08:14AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : March 23, 2017 Capital Cube
08:14AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : March 23, 2017
Mar-20-17 04:33PM  CRISPR THERAPEUTICS AG Files SEC form 8-K, Change in Directors or Principal Officers
10:23AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017 Capital Cube
10:23AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
Mar-16-17 02:12PM  [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage The Wall Street Journal
02:12PM  [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage at The Wall Street Journal
Mar-14-17 03:55PM  CRISPR to Use MaxCyte Cell Engineering Platform Investopedia
03:55PM  CRISPR to Use MaxCyte Cell Engineering Platform at Investopedia
07:00AM  CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte GlobeNewswire
Mar-10-17 04:23PM  CRISPR Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update GlobeNewswire
04:15PM  CRISPR THERAPEUTICS AG Files SEC form 10-K, Annual Report
Mar-02-17 04:30PM  CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference GlobeNewswire
Feb-28-17 08:00AM  CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation GlobeNewswire +18.95%
Feb-21-17 05:00AM  How Much Is a CRISPR Patent License Worth? at Forbes
Feb-17-17 02:36PM  Court Rules Against Berkeley In CRISPR Patent Case at Investopedia
Feb-16-17 05:45PM  Here's Why Editas Medicine Jumped 32.6% Higher Today at Motley Fool +16.29%
01:34PM  Both sides claim victory angling for millions in potential royalties and licenses in gene-editing patent dispute at bizjournals.com
Feb-15-17 06:28PM  CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents GlobeNewswire -7.88%
04:27PM  CRISPR THERAPEUTICS AG Files SEC form 8-K, Other Events, Financial Statements and Exhibits
03:52PM  Stop Freaking Out About CRISPR! (Except For One Thing) at Forbes
03:19PM  CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K. GlobeNewswire
03:19PM  Editas Medicine's stock soars after favorable ruling in CRISPR patent dispute at MarketWatch
02:37PM  Broad Institute wins case over gene-editing patents, boosting Editas shares at bizjournals.com
Feb-07-17 06:21PM  Why Crisper Therapeutics Tumbled 12.4% in January at Motley Fool
Feb-06-17 02:55PM  Biotech startup space Mass Innovation Labs eyes growth of its own at bizjournals.com
Feb-01-17 05:00AM  How A 2015 Trial Sheds Light On The CRISPR Patent Case at Forbes
Jan-24-17 10:15AM  CRISPR Therapeutics AG Value Analysis (NASDAQ:CRSP) : January 24, 2017
Jan-23-17 08:23AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : January 23, 2017 -7.30%
Jan-09-17 10:08PM  5 Ways Vertex Pharmaceuticals Plans to Grow in 2017 and Beyond at Motley Fool
01:15PM  Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerDec 04Sale19.4730,485593,5433,722,534Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerDec 01Sale19.1087,9911,680,6283,753,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 30Sale19.0412,666241,1613,841,010Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 29Sale19.254,26382,0633,853,676Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 28Sale19.225,08097,6383,857,939Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 27Sale19.7527,990552,8033,863,019Dec 07 09:57 AM
Bolzon Bradley J PhDDirectorNov 27Sale20.242004,04853,740Nov 28 04:10 PM
Woiwode ThomasDirectorNov 27Sale20.242004,0488,018Nov 28 04:11 PM
Woiwode ThomasDirectorNov 24Sale20.211,70034,3588,218Nov 28 04:11 PM
Bolzon Bradley J PhDDirectorNov 24Sale20.211,50730,45053,940Nov 28 04:10 PM
CELGENE CORP /DE/10% OwnerNov 24Sale20.0026,010520,2003,891,009Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 22Sale19.76256,0005,058,5603,917,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 20Sale19.02158,7183,018,8164,253,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 17Sale18.4451,282945,6404,411,737Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 16Sale18.39105,0001,930,9504,463,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 15Sale17.6715,000265,0504,568,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 14Sale17.1914,907256,2514,583,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 13Sale17.7665,0931,156,0524,597,926Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 10Sale17.2810,000172,8004,663,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 09Sale17.0820,000341,6004,673,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 08Sale18.0616,875304,7634,693,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 07Sale18.5423,000426,4204,709,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 06Sale18.8979,3271,498,4874,732,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 03Sale19.1022,759434,6974,812,221Dec 07 09:57 AM
Novak RodgerChief Executive OfficerSep 05Option Exercise1.813,8536,9741,151,860Sep 05 06:33 PM
Novak RodgerChief Executive OfficerSep 05Sale20.333,85378,3201,148,007Sep 05 06:33 PM
Novak RodgerChief Executive OfficerAug 31Sale20.8714,617305,0731,148,007Sep 05 06:33 PM